Automated Multiplex Simultaneous Gene-Related Testing System: Verigene® Bloodstream Infection Testing Panels
Keywords:
Verigene®, Sepsis, AntimicrobialsAbstract
The Verigene® bloodstream infection testing panels are an automated system
for genetic testing. It can simultaneously detect both bacteria and drug-resistance genes. This is useful for identifying appropriate therapeutic options for patients with sepsis. These testing panels were introduced for sale in 2016 and received insurance coverage in June 2017. The Verigene® system is 24–48 hours faster than the conventional method in terms of identifying major bacteria and detecting drug-resistance genes. This enables faster and more effective and appropriate antibacterial drug selection in the treatment of sepsis.
References
Yanagihara K, Garai T, Suzuki H, et al: Results of a questionnaire survey on genetic testing for infectious diseases. Journal of Infectious Diseases 92: 331-338, 2018
Japanese Society for Infectious Diseases, Committee on Infectious Disease Gene Testing, Japanese Society for Clinical Microbiology, Committee for New Tests in the Field of Infectious Diseases, 2018, Guidelines for Multi-Parameter Gene-Related Tests.
Suzuki S, Shibata N, Yamane K, et al., 2009, Change in the Prevalence of Extended-Spectrum-β-Lactamase-Producing Escherichia coli in Japan by Clonal Spread. J Antimicrob Chemother, 63: 72–79.
Suzuki H, Hitomi S, Yaguchi Y, et al., 2015, Prospective Intervention Study with a Microarray-Based, Multiplexed, Automated Molecular Diagnosis Instrument (Verigene system) for the Rapid Diagnosis of Bloodstream Infections, and its Impact on the Clinical Outcomes. J Infect Chemother 21: 849–856.
